Bifogade filer
Kurs & Likviditet
Kalender
2025-05-08 | Bokslutskommuniké 2025 |
2025-02-05 | Kvartalsrapport 2025-Q3 |
2024-11-06 | Kvartalsrapport 2025-Q2 |
2024-08-20 | X-dag ordinarie utdelning EQL 0.00 SEK |
2024-08-19 | Årsstämma 2025 |
2024-08-08 | Kvartalsrapport 2025-Q1 |
2024-05-14 | Bokslutskommuniké 2024 |
2024-02-14 | Kvartalsrapport 2024-Q3 |
2023-11-17 | Kvartalsrapport 2024-Q2 |
2023-08-18 | X-dag ordinarie utdelning EQL 0.00 SEK |
2023-08-17 | Årsstämma 2024 |
2023-08-16 | Kvartalsrapport 2024-Q1 |
2023-05-11 | Bokslutskommuniké 2023 |
2023-02-14 | Kvartalsrapport 2023-Q3 |
2023-02-13 | Kvartalsrapport 2023-Q3 |
2022-11-11 | Kvartalsrapport 2023-Q2 |
2022-10-26 | Extra Bolagsstämma 2022 |
2022-08-18 | X-dag ordinarie utdelning EQL 0.00 SEK |
2022-08-17 | Årsstämma 2023 |
2022-08-16 | Kvartalsrapport 2023-Q1 |
2022-05-13 | Bokslutskommuniké 2022 |
2022-02-16 | Kvartalsrapport 2022-Q3 |
2021-11-11 | Kvartalsrapport 2022-Q2 |
2021-08-19 | X-dag ordinarie utdelning EQL 0.00 SEK |
2021-08-18 | Kvartalsrapport 2022-Q1 |
2021-08-18 | Årsstämma 2022 |
2021-05-06 | Bokslutskommuniké 2021 |
2021-02-18 | Kvartalsrapport 2021-Q3 |
2020-11-06 | Kvartalsrapport 2021-Q2 |
2020-08-28 | X-dag ordinarie utdelning EQL 0.00 SEK |
2020-08-27 | Kvartalsrapport 2021-Q1 |
2020-08-27 | Årsstämma 2021 |
2020-05-04 | Bokslutskommuniké 2020 |
2020-02-05 | Kvartalsrapport 2020-Q3 |
2019-11-11 | Kvartalsrapport 2020-Q2 |
2019-08-23 | X-dag ordinarie utdelning EQL 0.00 SEK |
2019-08-22 | Kvartalsrapport 2020-Q1 |
2019-08-22 | Årsstämma 2020 |
2018-08-22 | Årsstämma 2019 |
2018-05-24 | X-dag ordinarie utdelning EQL 0.00 SEK |
2018-05-23 | Bokslutskommuniké 2018 |
2017-10-24 | Kvartalsrapport 2018-Q3 |
2017-08-21 | Kvartalsrapport 2018-Q2 |
2017-05-16 | X-dag ordinarie utdelning EQL 0.00 SEK |
2017-05-15 | Årsstämma 2018 |
2017-05-15 | Kvartalsrapport 2018-Q1 |
2017-02-08 | Bokslutskommuniké 2017 |
2016-10-25 | Kvartalsrapport 2017-Q3 |
2016-08-09 | Kvartalsrapport 2017-Q2 |
2016-05-19 | X-dag ordinarie utdelning EQL 0.00 SEK |
2016-05-13 | Årsstämma 2017 |
2016-05-13 | Kvartalsrapport 2017-Q1 |
2016-02-20 | Bokslutskommuniké 2016 |
2016-02-16 | Bokslutskommuniké 2016 |
2015-11-11 | Kvartalsrapport 2016-Q3 |
2015-10-09 | Extra Bolagsstämma 2016 |
2015-08-05 | Kvartalsrapport 2016-Q2 |
2015-05-19 | X-dag ordinarie utdelning EQL 0.00 SEK |
2015-05-18 | Kvartalsrapport 2016-Q1 |
2015-05-18 | Årsstämma 2016 |
2015-02-06 | Bokslutskommuniké 2015 |
2014-11-10 | Kvartalsrapport 2015-Q3 |
2014-08-13 | Extra Bolagsstämma 2015 |
2014-08-11 | Kvartalsrapport 2015-Q2 |
2014-05-13 | X-dag ordinarie utdelning EQL 0.00 SEK |
2014-05-12 | Årsstämma 2015 |
2014-05-12 | Kvartalsrapport 2015-Q1 |
2014-02-07 | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has today decided that Mellozzan (melatonin) tablets 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg should be included in the pharmaceutical benefit (reimbursement) system with a limitation to the indication "Insomnia in children and adolescents 6 - 17 years with ADHD where sleep hygiene measures have been insufficient".
5-7% of children and young people in Sweden have ADHD according to the National Board of Health and Welfare, and the incidence of children with sleep difficulties (insomnia) is very high, up to 80%, among these. The result is a vicious circle where lack of sleep aggravates ADHD symptoms during the day, which in turn negatively affects sleep at night. Not only the child, but also parents and other family members experience a reduced quality of life due to this, studies show", says Christer Fåhraeus, CEO of EQL Pharma. "Melatonin, which is the active substance in Mellozzan, is also a body-specific hormone and is today classified as the only permitted pharmaceutical for these children. But it is important that they do not take a larger dose than necessary, which is why we offer 6 different strengths. "
Christer Fåhraeus
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 - 60 90 00
E-mail:
Website: www.eqlpharma.com